Evidence map›Paper›PMID 33150476›Full record

ArticleMedical oncology (Northwood, London, England)2020

Back to (new) normality-A CODRAL/AIRO-L survey on cancer radiotherapy in Lombardy during Italian COVID-19 phase 2.

Barbara Alicja Jereczek-Fossa, Matteo Pepa, Giulia Marvaso, Johannes Lars Isaksson, Carlo Pietro Soatti, Luigi Franco Cazzaniga, Giovanni Battista Ivaldi, Marcello Amadori, Paolo Antognoni, Stefano Arcangeli and 28 more

Abstract readMulticenter Study
In one paragraph

Article in Medical oncology (Northwood, London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Barbara Alicja Jereczek-FossaDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435-20141, Milan, Italy.ORCID http://orcid.org/0000-0001-8151-3673
Matteo PepaDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435-20141, Milan, Italy. matteo.pepa@ieo.it.ORCID http://orcid.org/0000-0003-1338-9556
Giulia MarvasoDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435-20141, Milan, Italy.
Johannes Lars IsakssonDivision of Radiation Oncology, IEO, European Institute of Oncology, IRCCS, Via Ripamonti, 435-20141, Milan, Italy.
Carlo Pietro SoattiRadiation Oncology Centre, Ospedale Manzoni, Lecco, Italy.
Luigi Franco CazzanigaRadiation Oncology Centre, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Giovanni Battista IvaldiRadiation Oncology Centre, Istituti Clinici Scientifici Maugeri, IRCCS, Pavia, Italy.
Marcello AmadoriRadiation Oncology Centre, Ospedale C. Poma, Mantova, Italy.
Paolo AntognoniRadiation Oncology Centre, Ospedale di Circolo e Fondazione Macchi, ASST Dei Sette Laghi, Varese, Italy.
Stefano ArcangeliDepartment of Radiation Oncology, Policlinico S. Gerardo and University of Milan "Bicocca", Milano, Italy.
Alberto BuffoliRadiation Oncology Centre, Istituto Clinico S. Anna, Brescia, Italy.
Giancarlo BeltramoRadiation Oncology Centre, Centro Diagnostico Italiano (CDI), Milano, Italy.
Mario BignardiRadiation Oncology Centre, Fondazione Poliambulanza, Brescia, Italy.
Stefano BracelliRadiation Oncology Centre, Ospedale, Busto Arsizio, Italy.
Lorenza BruschieriDivision of Radiation Oncology, Ospedale Di Treviglio, Caravaggio Di Treviglio, Treviglio, Italy.
Simona CastiglioniRadiation Oncology Centre, S. Pio X-Humanitas, Milano, Italy.
Gianpiero CatalanoRadiation Oncology Centre, IRCCS Ospedale Multimedica, Sesto San Giovanni/Castellanza, Italy.
Nadia Di MuzioRadiation Oncology Centre, IRCCS Ospedale S. Raffaele and University Vita Salute, Milano, Italy.ORCID http://orcid.org/0000-0001-5961-411X
Carlo FallaiDivision of Radiotherapy, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milano, Italy.
Laura FariselliRadiotherapy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
Andrea Riccardo FilippiDivision of Radiotherapy, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy.
Alberto GramagliaRadiation Oncology Centre, Policlinico, Monza, Italy.
Corrado ItaliaRadiation Oncology Centre, Istituti Ospedalieri Bergamaschi, Ponte S. Pietro-Zingonia, Italy.
Fabrizio LombardiRadiotherapy Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy.
Stefano Maria MagriniRadiation Oncology Centre, Brescia University Radiation Oncology Department, O. Alberti Radium Institute, Spedali Civili Hospital, Brescia, Italy.
Simonetta NavaRadiation Oncology Centre, Istituti Clinici Di Pavia E Vigevano, Vigevano, Italy.
Ester OrlandiRadiation Oncology Centre, National Centre of Oncological Hadrontherapy, CNAO, Pavia, Italy.
Nadia PasinettiRadiation Oncology Department, Esine and University of Brescia, Esine, Italy.
Elena Lara SbicegoRadiation Oncology Centre, Istituto Clinico Sant'Ambrogio, Milano, Italy.
Luciano ScandolaroRadiation Oncology Centre, Ospedale Sant'Anna, ASST Lariana, Como, Italy.
Marta ScorsettiRadiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center - IRCCS, Rozzano, Milan, Italy.
Francesco StiglichRadiation Oncology Centre, Ospedale Di Sondrio, Sondrio, Italy.
Roberto TortiniOspedale Di Casalpusterlengo, Azienda Ospedaliera Della Provincia Di Lodi, Casalpusterlengo, Italy.
Riccardo ValdagniDepartment of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
Vittorio VavassoriUnit of Radiotherapy, Cliniche Gavezzeni SPA, Bergamo, Italy.
Sandro TonoliDivision of Radiation Oncology and Nuclear Medicine, ASST di Cremona, Cremona, Italy.
Mauro Filippo PalazziRadiotherapy Unit, ASST Ospedale Niguarda, Milano, Italy.
CODRAL (Board of Directors of Radiation Oncology Departments in Lombardy) network and of AIRO-L (Italian Association of Radiotherapy and Clinical Oncology – Lombardy)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundItaly experienced one of the world's severest COVID-19 outbreak, with Lombardy being the most afflicted region. However, the imposed safety measures allowed to flatten the epidemic curve and hence to ease the restrictions and inaugurate, on the 4th of May 2020, the Italian phase (P) 2 of the pandemic. The present survey study, endorsed by CODRAL and AIRO-L, aimed to assess how radiotherapy (RT) departments in Lombardy have dealt with the recovery. MATERIALS AND

methodsA questionnaire dealing with the management of pandemic was developed online and sent to all CODRAL Directors on the 10th of June 2020. Answers were collected in full anonymity one week after.

resultsAll the 33 contacted RT facilities (100%) responded to the survey. Despite the scale of the pandemic, during P1 14 (42.4%) centres managed to safely continue the activity (≤ 10% reduction). During P2, 10 (30.3%) centres fully recovered and 14 (42.4%) reported an increase. Nonetheless, 6 (18.2%) declared no changes and, interestingly, 3 (9.1%) reduced activities. Overall, 21 centres (63.6%) reported suspected or positive cases within healthcare workforce since the beginning of the pandemic. Staff units were quarantined in 19 (57.6%) and 6 (18.2%) centres throughout P1 and P2, respectively. In the two phases, about two thirds centres registered positive or suspected cases amongst patients.

conclusionThe study revealed a particular attention to anti-contagion measures and a return to normal or even higher clinical workload in most RT centres in Lombardy, necessary to carry out current and previously deferred treatments.

Indexed as

BetacoronavirusSurveys and QuestionnairesCoronavirus InfectionsCOVID-19Health PersonnelHumansItalyNeoplasmsOncology Service, HospitalPandemicsPersonal Protective EquipmentPneumonia, ViralSARS-CoV-2Cancer radiotherapyCOVID-19LombardyNorthern ItalySurvey

Identifiers

PMID33150476
PMCPMC7641253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.